Nuvaxovid Dispersion for Injection COVID19 Vaccine 5mcg/dose (recombinant, adjuvanted) in PFS
Product details
Registration number: SIN17384P
Classification: Prescription Only
Active ingredients: SARS-CoV-2 recombinant spike protein (Omicron JN.1)
Strength: 5 mcg/0.5ml
Dosage form: INJECTION, SUSPENSION
Route: INTRAMUSCULAR
Registrant: SANOFI-AVENTIS SINGAPORE PTE. LTD.
ATC code: J07BN04
HSA approval date: 4 November 2025
Manufacturer(s): Serum Institute of India Private Limited
Manufacturing country/countries: INDIA
What are the HSA registration number and classification for Nuvaxovid Dispersion for Injection COVID19 Vaccine 5mcg/dose (recombinant, adjuvanted) in PFS?
According to the HSA dataset updated 7 August 2026:
Registration number: SIN17384P
Classification: Prescription Only
What active ingredients and strength are recorded for Nuvaxovid Dispersion for Injection COVID19 Vaccine 5mcg/dose (recombinant, adjuvanted) in PFS?
According to the HSA dataset updated 7 August 2026:
Active ingredients: SARS-CoV-2 recombinant spike protein (Omicron JN.1)
Strength: 5 mcg/0.5ml
Ingredients and strengths are listed separately as recorded by HSA; their positions do not establish a one-to-one match. This is not a dosing instruction.
What dosage form and route are recorded for Nuvaxovid Dispersion for Injection COVID19 Vaccine 5mcg/dose (recombinant, adjuvanted) in PFS?
According to the HSA dataset updated 7 August 2026:
Dosage form: INJECTION, SUSPENSION
Route: INTRAMUSCULAR
Who is the recorded registrant for Nuvaxovid Dispersion for Injection COVID19 Vaccine 5mcg/dose (recombinant, adjuvanted) in PFS?
According to the HSA dataset updated 7 August 2026:
Registrant: SANOFI-AVENTIS SINGAPORE PTE. LTD.
Which manufacturers and countries are listed for Nuvaxovid Dispersion for Injection COVID19 Vaccine 5mcg/dose (recombinant, adjuvanted) in PFS?
According to the HSA dataset updated 7 August 2026:
Manufacturer(s): Serum Institute of India Private Limited
Manufacturing country/countries: INDIA
Where can I look up Nuvaxovid Dispersion for Injection COVID19 Vaccine 5mcg/dose (recombinant, adjuvanted) in PFS in the HSA register?
Open HSA’s therapeutic product register and search for registration number SIN17384P or the exact product name Nuvaxovid Dispersion for Injection COVID19 Vaccine 5mcg/dose (recombinant, adjuvanted) in PFS. The general register link does not preselect this product.
What are the source dates for this Nuvaxovid Dispersion for Injection COVID19 Vaccine 5mcg/dose (recombinant, adjuvanted) in PFS record?
This record is from HSA’s List of Registered Therapeutic Products on data.gov.sg. Dataset update: 7 August 2026. Retrieval date: 13 November 2026.
The dataset date is a snapshot date, not a separate current-register check for every product. Later direct checks are recorded separately.
Has this Nuvaxovid Dispersion for Injection COVID19 Vaccine 5mcg/dose (recombinant, adjuvanted) in PFS record had a separate HSA register check?
No separate current-register check is recorded for this product. Its presence in the imported dataset does not establish its current registration status.
Search the HSA register using SIN17384P for the latest record.
Sources and dates
HSA dataset: 2026. Updated: 13 November 2026.
Factual product information only; no dosing, treatment or suitability advice.
Updated and reviewed by: Dr Joel Lim MBChB UK (PG Dip Dermatology), Resident Physician.
.png)